武汉回盛生物科技股份有限公司 关于 2023 年度会计师事务所履职情况评估 暨审计委员会履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治 理准则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》和武汉回盛生 物科技股份有限公司（以下简称"公司"）《公司章程》《董事会审计委员会工 作细则》等规定和要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守， 认真履职。现将会计师事务所 2023 年度履职评估暨董事会审计委员会履行监 督职责的情况汇报如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 1、基本信息 中审众环会计师事务所（特殊普通合伙）（以下简称"中审众环"）始创于 1987 年，是全国首批取得国家批准具有从事证券、期货相关业务资格及金融 业务审计资格的大型会计师事务所之一。根据财政部、中国证监会发布的从事 证券服务业务会计师事务所备案名单，该所具备股份有限公司发行股份、债券 审计机构的资格。2013 年 11 月，按照国家财政部等有关要求转制为特殊普通 合伙制。首席合 ...

中信建投证券股份有限公司 关于武汉回盛生物科技股份有限公司 2023 年度募集资金存放与使用情况的专项核查报告 中信建投证券股份有限公司（以下简称"保荐机构"）作为武汉回盛生物科技股 份有限公司（以下简称"回盛生物""公司"）的保荐机构，根据《证券发行上市保 荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公 司自律监管指引第 13 号——保荐业务》等有关法律、法规和规范性文件的要求，对 回盛生物 2023 年度募集资金存放与使用情况进行了核查，具体情况如下： 一、募集资金基本情况 | | 项目 | | 金额（人民币元） | | --- | --- | --- | --- | | 2020 | 年收到募集资金净额 | | 850,712,520.80 | | 截至期初累计发生额 | | 项目投入 | 696,597,782.66 | | | | 补充流动资金 | 167,108,770.56 | | | | 利息收入扣减手续费净额 | 10,157,985.08 | | | | 理财收益 | 2,860,058.38 | | 本期发生额 | | 利息收入扣减手续费净额 | 2,897. ...

| 证券代码：300871 | 证券简称：回盛生物 | 公告编号：2024-050 | | --- | --- | --- | | 转债代码：123132 | 转债简称：回盛转债 | | 武汉回盛生物科技股份有限公司 关于回购注销 2021 年限制性股票激励计划限制性股票的公告 一、激励计划已履行的相关审批程序 （一）2021 年 6 月 28 日，公司召开的第二届董事会第十六次会议、第二 届监事会第十三次会议，审议通过了《关于<武汉回盛生物科技股份有限公司 2021 年限制性股票激励计划（草案）>及其摘要的议案》《关于<武汉回盛生 物科技股份有限公司 2021 年限制性股票激励计划实施考核管理办法>的议案》 《关于提请股东大会授权董事会办理 2021 年限制性股票激励相关事宜的议 案》及《关于核实<武汉回盛生物科技股份有限公司 2021 年限制性股票激励计 划激励对象名单>的议案》。公司独立董事对此发表了同意的独立意见，国浩 律师（深圳）事务所出具了法律意见书。 （二）2021 年 6 月 30 日至 2021 年 7 月 9 日，公司对本计划激励对象的 姓名和职务进行了内部公示。公示期内，公司监事会未收到 ...

Financial Performance - The company's net profit decreased year-on-year due to credit impairment losses for certain customers, high production costs of newly launched raw material drug projects, and a decline in sales revenue from chemical drug formulations[4]. - The company's revenue for 2023 was approximately ¥1.02 billion, a slight decrease of 0.31% compared to ¥1.02 billion in 2022[24]. - Net profit attributable to shareholders decreased by 68.16% to ¥16.78 million in 2023 from ¥52.71 million in 2022[24]. - The net cash flow from operating activities was ¥92.92 million, down 3.89% from ¥96.68 million in the previous year[24]. - Basic earnings per share fell by 68.27% to ¥0.1011 in 2023, compared to ¥0.3186 in 2022[24]. - The company's net assets attributable to shareholders decreased by 2.09% to ¥1.51 billion in 2023 from ¥1.54 billion in 2022[25]. - The company reported a significant increase in non-operating income, with government subsidies recognized amounting to ¥9.42 million in 2023, compared to ¥5.44 million in 2022[31]. - The company experienced a negative net profit of ¥11.19 million after deducting non-recurring gains and losses in 2023, compared to a positive net profit of ¥44.09 million in 2022[24]. - The weighted average return on equity decreased to 1.10% in 2023 from 3.36% in 2022[24]. - The company achieved operating revenue of CNY 1,019.76 million, a decrease of 0.31% compared to the same period last year[47]. - The annual operating cost for 2023 was 806.47 million yuan, an increase of 1.12% year-on-year, primarily due to low capacity utilization and high production costs in raw material projects[65]. - Net profit for 2023 was 16.78 million yuan, down 68.16% from the previous year, attributed to reduced demand for veterinary drugs in the struggling pig farming industry[65]. - The cash and cash equivalents at the end of 2023 amounted to 229.51 million yuan, a decrease of 17.62% year-on-year, mainly due to investments in fundraising projects and reduced net profit[65]. Market and Industry Trends - The veterinary medicine industry is transitioning towards high-quality development, with the sales growth rate of the veterinary medicine industry in China at 10.06% from 2018 to 2022, compared to a global growth rate of 2.86% during the same period[38]. - The scale of livestock farming in China has exceeded 70%, leading to an increase in the concentration of the veterinary medicine industry as large farming groups establish comprehensive evaluation systems for suppliers[36]. - The sales revenue of China's veterinary medicine industry reached 67.345 billion yuan in 2022, while the global veterinary medicine market was valued at 37.5 billion USD[38]. - The veterinary medicine market in China is characterized by a high proportion of chemical drugs at 75.40%, while biological products account for 24.60%[38]. Product Development and R&D - The company is focusing on the integration of raw materials and formulations to build competitive barriers in terms of cost advantages and quality control[38]. - The company is increasing investment in the research and development of pet medicines, aiming to capture the emerging market opportunities in this sector[38]. - The company has obtained 166 veterinary drug approval numbers as of December 31, 2023, indicating a strong product portfolio across various animal sectors[40]. - The company established a veterinary clinical trial center that received GCP certification in March 2024, enhancing its R&D capabilities[45]. - The company has developed a new generation of broad-spectrum, high-efficiency, low-toxicity veterinary antibiotics, such as the Tylosin injection, which has a long half-life and high drug concentration in the lungs[51]. - The company has signed new drug research agreements with several universities, enhancing collaboration in veterinary drug development[59]. - The company has a robust pipeline of research projects, including multiple patents filed and awarded, indicating a strong commitment to innovation[143]. Strategic Initiatives and Future Plans - The company plans to continue its market expansion and product development strategies to improve future performance[34]. - The company aims to rank among the top 20 global animal health companies, focusing on innovation and optimizing management mechanisms[113]. - The company plans to strengthen cooperation with large breeding groups and focus on sales targets through various means in the raw material sales sector[114]. - R&D project management will be emphasized to ensure timely acquisition of research results in key projects[114]. - The company will prioritize quality management to enhance product quality and maintain a "quality first" development philosophy[114]. - The company is committed to enhancing animal disease prevention and control levels, improving breeding efficiency, and contributing to animal welfare[40]. Corporate Governance and Management - The company has a complete corporate governance structure, including a shareholders' meeting, board of directors, and supervisory board, ensuring clear functional responsibilities[131]. - The company has maintained a clear separation between its operations and those of its controlling shareholders, with no institutional overlap[131]. - The company has established an independent financial department with a standardized accounting system and independent bank accounts, ensuring no shared accounts with controlling shareholders[130]. - The company emphasizes its commitment to research and development, with a focus on innovative products and technologies in the animal health sector[141]. - The management team is composed of experienced professionals with backgrounds in veterinary medicine, finance, and management, enhancing the company's operational capabilities[139][140]. - The company has a strong focus on compliance and governance, with regular evaluations of its board and management performance[147]. Employee and Shareholder Relations - The company emphasizes a comprehensive salary system and incentive mechanisms to ensure employee interests are protected[161]. - The company has established a training system that includes both internal and external training to enhance employee skills[162]. - The company distributed a cash dividend of RMB 3.00 per 10 shares, totaling RMB 49,049,431.50 (including tax) to shareholders[166]. - The company has implemented a stock incentive plan to attract and retain talent, with 48,800 shares granted at a price of 19.50 CNY per share[171]. - The company has ensured that minority shareholders have the opportunity to express their opinions and that their rights are protected[167]. Environmental Responsibility - The company strictly adhered to multiple environmental protection laws and standards during its operations, confirming its status as a key pollutant discharge unit[185]. - The total investment in environmental protection amounted to ¥71,851,740.79[195]. - The company paid an environmental protection tax of ¥100,969.36 for the year 2023[195]. - The company has established three wastewater treatment stations to handle production, clean, and domestic wastewater[188]. - The company emphasizes ecological protection and pollution prevention during its operations, adhering to environmental responsibilities and undergoing third-party evaluations of its environmental information[198].

Financial Performance - The company's revenue for Q1 2024 was ¥206,809,092.09, a decrease of 10.24% compared to ¥230,412,076.04 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥16,405,616.80, representing a decline of 210.43% from a profit of ¥14,855,718.00 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 206,809,092.09, a decrease of 10.3% compared to CNY 230,412,076.04 in the same period last year[25] - Net profit for Q1 2024 was a loss of CNY 16,405,616.80, compared to a profit of CNY 14,855,718.00 in Q1 2023, indicating a significant decline in profitability[27] - The weighted average return on equity was -1.08%, down from 0.96% in the same period last year, indicating a decline in profitability[5] Cash Flow - The net cash flow from operating activities was -¥46,279,493.65, a decrease of 169.38% compared to -¥17,180,234.31 in the same period last year[14] - Cash flow from operating activities showed a net outflow of CNY 46,279,493.65, worsening from a net outflow of CNY 17,180,234.31 in the same quarter last year[30] - The net cash flow from investment activities was -76,332,192.37 CNY, compared to -88,514,280.15 CNY in the previous year, indicating a slight improvement[31] - Cash inflow from financing activities totaled 202,776,473.00 CNY, up from 136,340,072.90 CNY year-over-year[31] - The net cash flow from financing activities increased to 95,204,302.87 CNY, compared to 64,595,118.87 CNY in the same period last year[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,993,838,428.76, reflecting a slight increase of 0.62% from ¥2,975,460,462.12 at the end of the previous year[5] - The total liabilities of the company increased to CNY 1,277,604,103.83, compared to CNY 1,265,980,935.65 in the previous quarter[20] - The total liabilities as of Q1 2024 amounted to CNY 1,484,056,241.74, compared to CNY 1,466,179,400.00 at the end of the previous year[23] - The total equity attributable to shareholders was CNY 1,509,782,187.02, slightly up from CNY 1,509,281,062.12 year-on-year[23] Expenses - Research and development expenses increased by 56.52% to ¥14,535,112.78 from ¥9,286,444.32 year-on-year[13] - The company reported a significant increase in financial expenses by 93.30% to ¥9,782,201.46, primarily due to the capitalization of convertible bond interest[13] - Total operating costs for Q1 2024 were CNY 219,314,493.26, slightly down from CNY 220,505,096.35 year-on-year[26] - The company recorded a significant increase in financial expenses, with interest expenses rising to CNY 10,410,980.81 from CNY 5,391,289.96 year-on-year[26] Shareholder Information - The company reported a total of 82,800,000 shares held by its largest shareholder, Wuhan Tongsheng Investment Co., Ltd., representing 49.91% of the total shares[17] Other Information - The company has not disclosed any new product developments or market expansion strategies in this quarter's report[18] - The company did not undergo an audit for the first quarter report[32] - The company began implementing new accounting standards starting in 2024[32]

我们认为，武汉回盛生物科技股份有限公司截至 2023 年 12 月 31 日止的《董事会关于 募集资金年度存放与实际使用情况的专项报告》已经按照中国证监会发布的《上市公司监管 指引第 2 号——上市公司募集资金管理和使用的监管要求》和《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》等有关规定编制，在所有重大方面如实反 映了武汉回盛生物科技股份有限公司截至 2023 年 12 月 31 日止的募集资金年度存放与实际 使用情况。 本鉴证报告仅供武汉回盛生物科技股份有限公司 2023 年年度报告披露之目的使用，不 得用作任何其他目的。 中审众环会计师事务所（特殊普通合伙） 中国注册会计师： 关于武汉回盛生物科技股份有限公司 募集资金年度存放与实际使用情况的鉴证报告 众环专字(2024)0100637 号 武汉回盛生物科技股份有限公司全体股东： 我们接受委托，对后附的武汉回盛生物科技股份有限公司（以下简称"回盛生物公司"） 截至 2023 年 12 月 31 日止的《董事会关于募集资金年度存放与实际使用情况的专项报告》 进行了鉴证工作。 按照中国证监会发布的《上市公司监管指引第 2 号—— ...

2023 年，武汉回盛生物科技股份有限公司（以下简称"公司"）董事会 严格按照《公司法》《证券法》等法律法规以及《公司章程》《董事会议事规 则》等有关规定，本着对股东负责的态度，恪尽职守、积极有效地行使职权， 规范运作、科学决策，认真贯彻落实股东大会的各项决议。现将 2023 年度公 司董事会工作情况汇报如下： 一、2023 年度公司总体经营情况 参阅公司《2023 年年度报告》之"第三节 管理层讨论与分析部分"。 二、2023 年董事会工作情况 （一）董事会会议召开情况 报告期内，公司董事会共召开 7 次会议，会议的召集及召开程序、召集人 和出席会议人员资格及表决程序均符合有关法律、法规、规范性文件及《公司 章程》的规定，会议决议均合法有效。具体情况如下： 武汉回盛生物科技股份有限公司 2023 年度董事会工作报告 | 会议届次 | 召开时间 | 审议议案 | | --- | --- | --- | | 第三届董事会 | 2023.02.24 | 审议通过《关于不向下修正"回盛转债"转股价格的议案》 | | 第二次会议 | | | | 第三届董事会 | 2023.04.10 | 审议通过《关于确认关联交易的 ...

武汉回盛生物科技股份有限公司 1 | 其它关联资金往来 | 资金往来方名称 | 往来方 与上市 公司的 | 上市公司核算 | 2023 年期初 | 2023 年度往来 | 2023 年度往 | 2023 年度偿 | 2023 年期末往 | 往来形 | 往来性质 （经营性往来、 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 的会计科目 | 往来资金余 | 累计发生金额 | 来资金的利 | 还累计发生 | 来资金余额 | 成原因 | | | | | 关联关 | | 额 | （不含利息） | 息（如有） | 金额 | | | 非经营性往来） | | | | 系 | | | | | | | | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | 垫付及 | | | | 湖北回盛生物科技 有限公司 | 子公司 | 其他应收款 | | 37,485.63 168,243,774.91 | | | 12,518,463.60 155,762 ...

| 证券代码：300871 | 证券简称：回盛生物 | 公告编号：2024-047 | | --- | --- | --- | | 转债代码：123132 | 转债简称：回盛转债 | | 武汉回盛生物科技股份有限公司董事会 关于 2023 年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求（2022 年 修订）》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式》之"第 21 号上市公司募集资金年度存放与使用情况的专项报告格式" 等有关规定，武汉回盛生物科技股份有限公司（以下简称"公司"或"本公司"）董事会编 制了 2023 年度募集资金存放与使用情况的专项报告。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 1、首次公开发行股票募集资金 经中国证券监督管理委员会《关于同意武汉回盛生物科技股份有限公司首次公开发行 股票 ...

因此，公司总股本相应增加 72 股，注册资本增加 72.00 元，公司总股本 将由 165,887,158 股变更为 165,887,230 股，注册资本将由 165,887,158 元变更 为 165,887,230 元。 | 证券代码：300871 | 证券简称：回盛生物 | 公告编号：2024-051 | | --- | --- | --- | | 转债代码：123132 | 转债简称：回盛转债 | | 武汉回盛生物科技股份有限公司 关于变更注册资本暨修改《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 武汉回盛生物科技股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日召开第三届董事会第十一次会议，审议通过了《关于变更注册资本暨修改< 公司章程>的议案》，本议案尚需提请公司股东大会审议。现将相关事项公告 如下： 一、注册资本变更 （一）增加注册资本情况 公司 2021 年向不特定对象发行可转换公司债券"回盛转债"的转股期为 2022 年 6 月 23 日至 2027 年 12 月 16 日。"回盛转债"于 2022 年 ...